疑难病杂志2026，Vol.25Issue(5)：525-529,546,6.DOI:10.3969/j.issn.1671-6450.2026.05.003
18 F-FDG PET/CT 联合血清 ANXA2、CXCL16 对非小细胞肺癌患者新辅助化疗疗效的评估价值
The evaluation value of 18 F-FDG PET/CT combined with serum ANXA2 and CXCL16 for the efficacy of neoadjuvant chemotherapy in patients with non-small cell lung cancer
摘要
Abstract
Objective To explore the evaluation value of 18 F-FDG PET/CT combined with serum annexin A2(ANXA2)and C-X-C motif chemokine ligand 16(CXCL16)for the efficacy of neoadjuvant chemotherapy(NAC)in patients with non-small cell lung cancer(NSCLC).Methods From April 2023 to June 2025,180 NSCLC patients treated in the De-partment of Nuclear Medicine at Xuzhou First People's Hospital(Xuzhou Medical University Affiliated Xuzhou Municipal Hospital)were studied(all received NAC treatment).Based on NAC efficacy,they were divided into an effective group(119 cases)and an ineffective group(61 cases).Logistic regression was used to analyze the influencing factors of NAC efficacy in NSCLC patients,and relative risk was used to analyze the risk of treatment failure at different levels of ANXA2 and CXCL16.ROC curve analysis was used to evaluate the value of predicting NAC efficacy in NSCLC patients.Results The expression levels of MTV,TLG,serum ANXA2,and CXCL16 in the ineffective group were all significantly higher than those in the ef-fective group(t/P=7.685/＜0.001,6.494/＜0.001,7.789/＜0.001,7.906/＜0.001).Poorly differentiated tumor cells,high MTV,high TLG,high serum ANXA2,and high CXCL16 were independent risk factors for poor NAC response[OR(95％CI)=3.056(1.334-7.002),2.703(1.383-5.284),2.238(1.270-3.943),2.815(1.342-5.905),2.976(1.380-6.417)].The risk of NAC treatment failure in patients with high expression of ANXA2 and CXCL16 was 1.576 times and 1.620 times that of those with low expression,respectively[95％CI=(1.209-2.053),(1.256-2.088)].The AUCs for evaluating NAC efficacy in NSCLC patients using MTV,TLG,serum ANXA2,CXCL16,and their combination were 0.738,0.727,0.760,0.770,and 0.912,respectively.The combined assessment of the four indicators was superior to each individual assessment(Z=2.512,2.537,2.493,2.486;all P＜0.001).Conclusion MTV,TLG,and serum levels of ANXA2 and CXCL16 are elevated in NSCLC patients who do not respond to NAC treatment.Combined detection of these markers demonstrates high value in eval-uating the efficacy of NAC treatment in NSCLC patients.关键词
非小细胞肺癌/新辅助化疗/18 F-FDG PET/CT/膜联蛋白A2/C-X-C基序趋化因子配体16/疗效评估Key words
Non-small cell lung cancer/Neoadjuvant chemotherapy/18 F-FDG PET/CT/Annexin A2/C-X-C motif chemokine ligand 16/Therapeutic effect eveluation分类
医药卫生引用本文复制引用
陆园,王伟,张翔,任蒙蒙,宋英健,陈领振..18 F-FDG PET/CT 联合血清 ANXA2、CXCL16 对非小细胞肺癌患者新辅助化疗疗效的评估价值[J].疑难病杂志,2026,25(5):525-529,546,6.基金项目
江苏省卫生健康委2022年度医学科研立项项目(KJS2022H0030) Medical Research Project Approved by the Health Commission of Jiangsu Province for the Year 2022(KJS2022H0030) （KJS2022H0030）
